New Treatment Combo Shows Promise for Advanced Parkinson's Disease
- Authors
- G Niraj, N Charan, Shruti Niraj, Varsha B Karanth, Lakshmanan Prakash
- Journal
- Cureus
- Year
- 2026
- DOI
- 10.7759/cureus.101146
- Study Type
- Human
- Outcome
- Positive
- Peer Reviewed
- Yes
- Country
- India
- Health Condition
- Parkinson's Disease
- Body System
- Nervous System
TL;DR
A small case series reported improved symptoms and quality of life in advanced Parkinson’s disease patients following a multimodal precision health program.
Key Finding
__no_content__
Summary
This case series described three patients with advanced idiopathic Parkinson’s disease who underwent a 12-week precision health optimization program that included dual stellate ganglion block, nutraceutical infusions, and extracorporeal blood ozone therapy. The intervention aimed to address autonomic imbalance, oxidative stress, neuroinflammation, and mitochondrial dysfunction—processes implicated in Parkinson’s disease pathophysiology. At 12 weeks, all patients reported reduced disease severity and improved quality of life based on validated outcome measures. However, the findings are limited by the very small sample size, lack of a control group, and potential placebo effects, and therefore require confirmation in controlled clinical trials.
Abstract
Parkinson's disease (PD) is reported to be the fastest-growing neurodegenerative condition with significant management challenges. Neurobiology is linked to mitochondrial dysfunction, oxidative stress, autonomic imbalance, and neuroinflammation. There is progressive propagation of alpha-synuclein protein in neural networks and dopamine deficiency in the nigrostriatal pathway. Levodopa remains the gold standard agent in its management. However, the non-motor symptoms that significantly compromise quality of life remain largely unresponsive to levodopa. Currently, there are no interventions that can modify disease progression. Following a comprehensive assessment by an interdisciplinary team, three patients with advanced idiopathic PD were treated with a precision health optimization program. The program included dual stellate ganglion block, nutraceutical infusions, and extracorporeal blood ozone therapy. The program targets the underlying autonomic imbalance, oxidative stress, neural inflammation, and mitochondrial dysfunction. Validated outcome measures were completed at baseline and at the 12-week review. At the 12-week review following the program, all three patients reported a reduction in disease severity with an improvement in quality of life. The innovative precision health optimization program could have a role in the management of advanced PD. Limitations include a small patient cohort, the absence of a control arm, and potential placebo effects.